Elevation Oncology, Inc.
ELEV evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- EO-1022 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ELEV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
EO-1022 (Preclinical)
Next Catalyst
—
Tracking 4 pipeline candidates for Elevation Oncology, Inc..
Run Elevation Oncology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Elevation Oncology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Elevation Oncology, Inc.'s lead drug candidate?
Elevation Oncology, Inc.'s most advanced tracked candidate is EO-1022 (Preclinical) for Treatment of patients with HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer (and other solid tumors).
Who is the CEO of Elevation Oncology, Inc.?
Chief Executive Officer is the chief executive officer of Elevation Oncology, Inc. (ELEV).
What therapeutic areas does Elevation Oncology, Inc. focus on?
Elevation Oncology, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.